Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-01 EDT			5-day change	1st Jan Change
11.83 ^USD	-2.07%		-2.23%	+73.46%

07-01	Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO	MT
07-01	Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer	07-01	AQ
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting	06-07	AQ
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer	06-05	AQ
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting	06-01	AQ
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting	06-01	AQ
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments	05-07	AQ
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	04-26	AQ
Y-mAbs to Present at 2024 ASCO Annual Meeting	04-25	AQ
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	03-14	AQ
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	03-04	AQ
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	03-04	PU
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	02-29	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	02-21	AQ
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024	02-16	AQ
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	01-02	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	12-22	AQ
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index	12-13	AQ
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	11-13	AQ
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023	23-10-31	AQ
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director	23-10-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Press Releases

Filters